autologous cd34+ hematopoietic progenitor cells transduced with anti-hiv-1 ribozyme
Vaccineexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2002 (NCT00074997)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous cd34+ hematopoietic progenitor cells transduced with anti-hiv-1 ribozyme
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01177059 | Phase 2 | Dec 1, 2004 | Johnson and Johnson |
| NCT00074997 | Phase 2 | Dec 1, 2002 | Johnson and Johnson |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 2 | 2 | 1 | 2002 |
1 organizations
Page 1 / 1